Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. - Wikidata - wikimedia - TriplyDB

Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.

Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.

http://www.wikidata.org/entity/Q34129628

about

Early diabetic nephropathy in type 1 diabetes: new insights Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology Urinary proteomics to support diagnosis of stroke Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.Application of Proteomic Analysis to Renal Disease in the Clinic.Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria Excretion of urinary orosomucoid 1 protein is elevated in patients with chronic heart failure.Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.CKD273, a new proteomics classifier assessing CKD and its prognosis Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies.Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes Urine proteomics in the diagnosis of stable angina.Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension.Differential urinary glycoproteome analysis of type 2 diabetic nephropathy using 2D-LC-MS/MS and iTRAQ quantification.Novel biomarkers in type 1 diabetes.Nanocarriers for pulmonary administration of peptides and therapeutic proteins.CE-MS in biomarker discovery, validation, and clinical application.Urinary proteomics in cardiovascular disease: Achievements, limits and hopes.Clinical application of urinary proteomics/peptidomics.Proteomic biomarkers in kidney disease: issues in development and implementation.Body fluid peptide and protein signatures in diabetic kidney diseases.Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease.Prediction of remission after metabolic surgery using a novel scoring system in type 2 diabetes - a retrospective cohort study.Urine protein biomarkers for detection of cardiovascular disease and their use for the clinic.Detection of a Peptide Biomarker by Engineered Yeast Receptors.A urinary proteome-based classifier for the early detection of decline in glomerular filtration.Urinary proteomic biomarkers to predict cardiovascular events How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease

P2860

Q27021632-C728E246-B084-4EE6-B639-5535519B6406 Q28475613-282C0C83-E5DE-4E04-8A00-8FED34948F56 Q28483776-6C83F39E-ADDD-4552-8D31-F0D3AE6E295A Q28484968-6C4841C6-D83B-49CA-9F16-C8A56DB7B060 Q28748796-A034B3F8-A454-4D89-B184-F077B82AE0B6 Q30438814-B317D557-CE1A-47EB-980F-D7F0DD9CDF39 Q33436829-B9E1D73B-D7BD-406D-BB6A-3F69306E4B2C Q33575004-4DA05E33-9C25-407D-9094-AFC80BA68D46 Q33735287-B79346D6-3DD8-4CBA-A8C8-52B57E241FFA Q34172662-C7670A2B-A233-4FF9-8F1A-9DB2523BE2C5 Q34725022-4B638F50-78C5-4AA1-9778-EB733C667EB0 Q34729912-C6C7846E-6DC0-4DC1-87A3-88A2E1C1CFE2 Q35460015-3919E1D9-8EE5-4D0B-8B55-C7917D22711E Q35878999-C95496B6-9A21-4E2C-8EB7-0BD6A1E62230 Q35994430-21E63263-44D0-4164-BF9C-3E980C633CBA Q36250869-FFB80A24-B94E-4E6C-9D78-E8FE7D297762 Q36321624-B773AD51-0CA4-4F28-B2AA-283018DE16FA Q37088197-BB8819DC-9D2E-4D39-A275-6ACD89513D7E Q37823598-EC5D62E6-BFE8-4E41-B04B-9B48BF2D4E58 Q37833587-A0205D04-94F3-4BB1-BB3C-EC91FD1661C4 Q37869464-3B28E3BD-4F1B-4F9C-A722-46D98E723001 Q37945790-46CD1A5E-C3BE-47FF-8515-DCBE9C9D49D1 Q38341211-46572E97-1202-4232-AB2B-DA9CEE0DDC99 Q38553924-ECB558D8-57B7-415D-9CC0-BCCDAD1C262F Q39094572-4913E3AA-9B15-4C0B-BC1C-ED65BDADFFDD Q39427234-E033A6EA-381C-4599-82AF-E23359B5DAB1 Q43032395-06D622B4-7A93-4F7F-AAA6-186599FFDF6B Q47638470-99F5FDDE-D3EA-42C9-BF94-41F97E126147 Q48173200-35685FC1-13C1-482D-AF42-C3C24173884A Q49037974-1E40A48A-C3B3-4D12-8E9D-C228BD47667A Q56970450-07F87050-3972-40E5-9561-463980551054 Q57711927-A5812BE2-D7D8-4D8B-A4EB-6FA3B7429CAF Q58107393-0A4A298B-7E6C-4E84-B331-F7A6AD64326C

P2860

Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.

http://www.wikidata.org/entity/Q34129628

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@ast

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@en

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@nl

type

label

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@ast

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@en

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@nl

prefLabel

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@ast

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@en

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@nl

P1433

Q34129628-75E1D44B-48B9-425B-A6A9-D33459EF6B56

P1476

Q34129628-49DBB71D-6D73-4B39-AAB2-EFA46CD84572

P2093

Q34129628-0BD00654-88C7-4958-B761-0390C0505981

Q34129628-51FD7C31-1401-4708-9FF5-6B7A3F91DAEF

Q34129628-9B205E19-7C96-482C-B3AF-CF422B34F56C

Q34129628-DA6CCA99-2DCB-440A-BBA3-903C8FBC08ED

Q34129628-FDF79705-999A-41C0-BE5A-643A29993F3F

P2860

Q34129628-047EFC38-A2E6-4479-9577-060CCCB5D3F6

Q34129628-097A1F5B-2C1F-432B-957E-CFA2A70DFAC0

Q34129628-123929AD-A278-40F2-877A-C028AF35BC1A

Q34129628-18AE3A31-0D49-4AE7-89CC-313339525A52

Q34129628-1BC1F5CD-EBA5-486D-9277-1E61327D2BD9

Q34129628-1F223FDF-2C61-43E7-B714-7045ACDB0B91

Q34129628-21B6DB1A-D5E0-4F55-B15C-DDF65171E22C

Q34129628-25B273FE-1905-41DD-8481-04C87AA6E92F

Q34129628-45BF9BC6-8DA1-4A86-95DD-DA868CCA0CA4

Q34129628-46A3F582-DCB5-40C5-8022-16E48B1E6709

P304

Q34129628-8B9F180F-07A8-4CFD-8021-00EA3DBE3374

P31

Q34129628-19728B8C-17BD-44D1-A33D-2CBDEE435776

P356

Q34129628-0A2EFE9A-F5D7-4454-82F1-BDFFEED05DD6

P433

Q34129628-02E5003B-6319-4755-9841-446E36227AD3

P478

Q34129628-AA91EA97-11AB-4B62-B5A8-4C8A4F236F81

P50

Q34129628-05B9A481-9C74-4CB4-9486-BAD41DF749D4

Q34129628-7ECCF093-3503-4643-B08E-169FCA6392C1

Q34129628-930C4006-CBED-4AC1-8632-74F74609E2A8

P577

Q34129628-C0BC5122-CA7D-4EA2-B724-FC14B4963992

P5875

Q34129628-B1DFEA21-EB06-49ED-BFE0-BA7E1EB0538D

P698

Q34129628-8A520B63-E42A-4C80-8D43-932698892F39

P921

Q34129628-2197AEB2-1C7A-486B-AE02-CF0BA9F93A86

P932

Q34129628-CB6BD583-F1B6-476C-B58D-0AE28E4DE5AB

P356

P1433

Diabetes technology & therapeutics

P1476

Evaluation of urinary biomarke ...... , and diabetic kidney disease.

@en

P2093

David M Maahs

http://www.w3.org/2001/XMLSchema#string

Eric Schiffer

http://www.w3.org/2001/XMLSchema#string

Janet K Snell-Bergeon

http://www.w3.org/2001/XMLSchema#string

John E Hokanson

http://www.w3.org/2001/XMLSchema#string

Lorraine G Ogden

http://www.w3.org/2001/XMLSchema#string

P2860

The minimum information about a proteomics experiment (MIAPE)

CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.

Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine.

Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.

Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry.

Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches.

Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry.

High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine

Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease.

Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/DIA.2008.0040

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Gregory L. Kinney

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23767606

http://www.w3.org/2001/XMLSchema#string

P698

19132849

http://www.w3.org/2001/XMLSchema#string

P921

P932

2939844

http://www.w3.org/2001/XMLSchema#string